Monday, January 24, 2022
More

    Latest Posts

    Pfizer, Moderna already planning for omicron variant of COVID-19 – Riverside, California

    Riverside, California 2021-11-27 18:14:17 –

    Pfizer and Modana said they have plans to address vaccine-resistant mutants. Moderna said it has already tested high dose boosters.

    With the appearance of Omicron COVID-19 variantIs currently detected in Southern Africa, Europe, Israel and Hong Kong, and many pharmaceutical companies have announced plans to apply vaccines as needed.

    Scientists say there’s still a lot to learn about New variant, Listed by the World Health OrganizationVariant of concern.. They know that Omicron is genetically different from its predecessor. variant It contains beta and delta variants, but it is unclear whether these genetic changes make it more contagious or dangerous.So far, there are no signs Mutant Causes more serious illness.

    Also, Omicron is more infectious and can take weeks to determine if the vaccine is still effective.

    AstraZeneca, Moderna, Novavax and Pfizer have already stated plans to address this. Pfizer and its partner BioNTech said they are monitoring variants that may avoid the mRNA vaccine.

    “If a vaccine escape variant emerges, Pfizer and BioNTech expect to be able to develop and manufacture a tailor-made vaccine for that variant in about 100 days, subject to regulatory approval,” Pfizer said in a statement. Stated.

    Since early 2021, Moderna has identified three response options, stating that it has developed a strategy to address new concerns. The first is to double the current dose of COVID-19 booster from 50 micrograms to 100 micrograms.

    “A 100 (microgram) dose of mRNA-1273 has also recently been studied by the National Institutes of Health (NIH) in the United States and generally provides the highest neutralizing titer for previous SARS-CoV-2 strains. “It was,” said Moderna. statement. It is said that 306 people have already been administered to test its safety and efficacy.

    Moderna said the second strategy is to test two multivalued booster candidates designed to predict mutations such as those found in Omicron variants.

    The third is the rapid development of Omicron-specific boosters. The company said it is already working on other variants, including Delta. Moderna said booster candidates could be put into clinical trials within 60-90 days.

    Moderna, Pfizer, Johnson & Johnson are the only manufacturers using vaccines that are licensed for use in the United States. The Food and Drug Administration and the US Centers for Disease Control and Prevention recently granted booster immunity to all adults and approved combination options. Therefore, fully vaccinated people can get the boosters they want or have available.

    Professor Andrew Pollard, director of the Oxford Vaccine Group, who developed the AstraZeneca vaccine, was cautiously optimistic that existing vaccines could be effective in preventing serious diseases caused by Omicron mutants, and most mutations. Said they seemed to be in a similar area. In other variants.

    “We are optimistic that the vaccine will also work against new variants of serious illnesses, at least from a speculative point of view, but in reality we have to wait a few weeks for it to be confirmed.” He told BBC Radio.

    Some experts said the emergence of this variant indicates that vaccine storage by developed countries could prolong the pandemic.

    In Africa, less than 6% of people are fully immunized to COVID-19, and millions of healthcare workers and vulnerable people have not yet received a single dose. These conditions accelerate the spread of the virus and increase the chances of it evolving into a dangerous variant.

    “One of the key factors in the emergence of variants could be low vaccination rates in parts of the world. WHO requires us all to be safe and careful. Until then, we warn that no one is safe, “says Professor Peter Openshaw. Of Experimental Medicine at Imperial College London.

    South Africa has about 20 million doses of vaccine manufactured by Pfizer and Johnson & Johnson, but the number of people vaccinated is about 120,000 per day, a government target of 300,000 per day. Far below the number of people.

    The Associated Press Maria Cheng and Pan Pylas contributed to this report.

    Pfizer, Moderna already planning for omicron variant of COVID-19 Source link Pfizer, Moderna already planning for omicron variant of COVID-19

    The post Pfizer, Moderna already planning for omicron variant of COVID-19 – Riverside, California appeared first on Eminetra.

    Latest Posts

    Don't Miss

    Stay in touch

    To be updated with all the latest news, offers and special announcements.